📼 Watch UCLH's new film that seeks to support members of Black communities who want to take part in health research.

The film shares stories from people involved in the @nihr.bsky.social Improving Black Health Outcomes theme, highlighting why they joined and what representation means in research.

💡 A new gene therapy for Huntington’s disease, AMT-130, has shown it can significantly slow disease progression by 75% over 3 years.

The phase I/II study, led by @ucl.ac.uk researchers and taking place at @uclh.bsky.social and other sites, offers new hope for families affected by this disease.

🧠 New analysis in @thelancet.com has shown, for the first time, that Alzheimer’s drugs lecanemab and donanemab can slow disease progression.

The anti-amyloid antibody medications allow patients to preserve functional independence.

@uclh.bsky.social @ucl.ac.uk @uclbrainscience.bsky.social

Last chance to register - deadline tomorrow ⏰

Join our online workshop 'Intro to PPI & Ethical Considerations'

📅 Thursday 25 Sept, 10am-12:30pm

The workshop will cover:
- Why PPI matters in research
- Practical approaches to involvement
- Ethical principals

And well done to all shortlisted in the category:

- Prof Sanjay Sisodiya, Consultant Neurologist,
National Hospital for Neurology & Neurosurgery

- Sickle Cell & Thalassemia Alliance for Research, STAR Research Nursing Team

- Lucy Wellings, Lead Children & Young People Research Nurse, Paediatrics

“Winning the World Class Research Award is a very proud moment for the team. It recognises the dedication, collaboration & resilience that go into delivering world-leading cancer research and the difference we make for our patients."

- Lydia Ward, Head of the CCTU

🏆 Huge congratulations to the Cancer Clinical Trials Unit (CCTU) at @uclh.bsky.social on winning the Contribution to World Class Research Award at the University College London Hospitals NHS Foundation Trust Celebrating Excellence Awards 2025.

A @ucl.ac.uk-led trial is investigating a simple blood test that could transform how Alzheimer’s disease is diagnosed.

The ADAPT study aims to demonstrate that measuring protein (p-tau217) levels can deliver earlier, fairer access to diagnosis & future NHS treatments.

🔬 Major UK trial, published in @thelancet.com, finds sinus surgery is more effective than antibiotics for chronic rhinosinusitis (CRS).

The trial was led by @ucl.ac.uk alongside academics from @uniofeastanglia.bsky.social and Guy’s and St Thomas’ NHS Foundation Trust.

💊 A once-daily tablet, baxdrostat, has been shown to significantly lower blood pressure in patients whose blood pressure remains high despite taking several existing medicines.

Results are from the global BaxHTN trial, led by @ucl.ac.uk's Professor Bryan Williams.

Sinus surgery is more effective than antibiotics at treating chronic rhinosinusitis, finds a major clinical trial led by @uclbrainscience.bsky.social @uclhresearch.bsky.social with academics at @uniofeastanglia.bsky.social and Guy’s and St Thomas’ in @thelancet.com, with @nihr.bsky.social funding

📃 Check out page 29 of the NIHR 2024/25 Annual Report for a feature on new cancer immunotherapy trials at @uclh.bsky.social - supported by our Biomedical Research Centre & Clinical Research Facility.

www.nihr.ac.uk/about-us/who...

New to Patient and Public Involvement (PPI)?

Join our 'Intro to PPI and Ethical Considerations' workshop, designed for anyone looking to understand the foundations of meaningful patient engagement in research.

📅 25 September, 10am to 12.30pm
💻 Online
Sign up now ⬇️

🍽️ A new clinical trial, led by clinicians at UCL and UCLH, suggests eating less processed food could help sustain a healthy weight long term.

When given nutritionally matched diets, trial participants lost twice as much weight eating minimally processed vs ultra-processed foods.

A UCL & UCLH-led study has shown that prostate cancer patients with certain molecular features respond better to immunotherapy than previously thought.

The multicentre NEPTUNES trial suggests treatment with immunotherapies (nivolumab & ipilimumab) could benefit ~25% of patients with this cancer.